AI & Tech · London
Isomorphic Labs raises $5bn in AI drug discovery round led by Sequoia and Greenoaks
Isomorphic Labs, the London-based AI drug discovery company led by Demis Hassabis, announced the round on Tuesday, 17 November. The company did not disclose its valuation, though Bloomberg had reported about $50bn earlier in November.
AI text based on reports by The Telegraph, Handelsblatt, TechCrunch and other publishers. Published . How it is made
For membersThe first 30 seconds for everyone. Synthetic voice (AI).
In brief
Greenoaks and Sequoia Capital co-led the Series C round, which Isomorphic announced on Tuesday, 17 November. Andreessen Horowitz joined as a new investor.
Isomorphic did not disclose its valuation. Bloomberg reported in November that the round would value the company at about $50bn.
Hassabis said in January that first clinical trials were expected by the end of 2026. He gave no updated target and said more announcements would come in 2027.
The round follows a $2.1bn Series B in May 2026. The company has raised nearly $8bn in roughly eighteen months, with more than 20 programmes under way.
A $5bn round led by two growth investors
Isomorphic Labs, the London-based company that uses artificial intelligence to design new medicines, announced on Tuesday, 17 November, that it has raised $5bn in a Series C funding round. Sequoia Capital and Greenoaks co-led the round. Andreessen Horowitz came in as a new investor, while existing backers took part too, among them Alphabet's GV and CapitalG, Thrive Capital, MGX, Temasek and the UK Sovereign AI Fund. The company said investors oversubscribed the round.
Valuation and funding history
The company did not disclose its valuation. Bloomberg had reported earlier in November that the round would value Isomorphic at about $50bn. The money follows a $2.1bn Series B in May 2026, only about six months earlier. Across roughly eighteen months the company has raised nearly $8bn, even though it has not yet developed a medicine and has missed timelines it set for itself.
- 2026-05
- 2.1 $bn
- 2026-11-17
- 5 $bn
Data from the article text
Pipeline and trial timeline
Isomorphic was spun out of Google DeepMind in 2021 and builds an AI drug-design engine, IsoDDE, that runs many simulation models across chemistry. The company says the engine is producing positive preclinical results in its own oncology and immunology programmes and with partners. More than 20 programmes are under way, and pharma partners include Eli Lilly, Novartis and Johnson & Johnson.
In January, Hassabis said Isomorphic expected its first clinical trials by the end of 2026. He did not give Bloomberg an updated target, but said the company is on track with its regulatory submissions and will have more to announce in 2027. Regulators have not yet approved any drug designed with AI.
Leadership and the platform plan
Hassabis stepped back as chief executive of Google DeepMind in August, during an Alphabet reorganisation. He is now DeepMind's chair and Alphabet's chief scientist, and he remains Isomorphic's chief executive. The new round is the company's first since that change. Hassabis told Bloomberg the money will speed the move toward clinical trials, and that the company will extend beyond small-molecule drugs into large-molecule biologics as well.
Hassabis described the goal in broad terms:
“What we're trying to build is a platform to do hundreds of drugs a year.”
Investor rationale
Sequoia partner Konstantine Buhler framed the investment around the underlying technology.
“Isomorphic Labs is building foundational technology for the future of medicine.”
Buhler told Bloomberg that Sequoia backed the company because its models have shown scaling laws, meaning performance keeps improving as they receive more computing power and data.
Ask about this text
Sources and context
- The TelegraphBritish tech entrepreneur raises $5bn for AI drug discovery company
- HandelsblattPharma: Europe's most valuable AI companyPharma: Europas wertvollste KI-Firma - Milliarden für Isomorphic Labs · original in German
- TechCrunchIsomorphic Labs raises $5B as it looks to take drug candidates to clinical trials
- HandelsblattAI: Start-up from Nobel laureate raises billions againKI: Start-up von Nobelpreisträger sammelt erneut Milliarden ein · original in German
- Demis Hassabis
- Founder and chief executive of Isomorphic Labs, now chair of Google DeepMind and Alphabet's chief scientist
- Places
- London
Pollar is free and carries no ads in the text. Its members keep it going.
Support Pollar